NASDAQ: VIR - Vir Biotechnology, Inc.

Yield per half year: +3.88%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Vir Biotechnology, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Vir Biotechnology, Inc.

Vir Biotechnology, Inc., компания, занимающаяся иммунологией на клинической стадии, разрабатывает терапевтические продукты для лечения и профилактики серьезных инфекционных заболеваний. Он разрабатывает VIR-2218 и VIR-3434 для лечения вируса гепатита B; VIR-2482 для профилактики вируса гриппа A; VIR-1111 для профилактики вируса иммунодефицита человека; и ВИР-2020 для профилактики туберкулеза.

more details
Компания имеет соглашения о грантах с Фондом Билла и Мелинды Гейтс и Национальными институтами здравоохранения; опцион и лицензионное соглашение с Brii Biosciences Limited и Brii Biosciences Offshore Limited; соглашение о сотрудничестве и лицензионное соглашение с Alnylam Pharmaceuticals, Inc .; соглашение о сотрудничестве, лицензии и опционное соглашение с Visterra, Inc .; лицензионные соглашения с Университетом Рокфеллера и MedImmune, Inc .; сотрудничество с WuXi Biologics; и соглашение о совместных исследованиях с Generation Bio., а также с GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA. и Alnylam Pharmaceuticals, Inc. Он также имеет производственное соглашение с Samsung Biologics Co., Ltd. для производства антител против SARS-COV-2 для потенциального лечения COVID-19. Vir Biotechnology, Inc. была основана в 2016 году, ее штаб-квартира находится в Сан-Франциско, Калифорния.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2019-10-11
ISIN US92764N1028
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Сайт https://www.vir.bio
Цена ао 9.11
Change price per day: 0% (9.11)
Change price per week: -10.95% (10.23)
Change price per month: -10.9% (10.225)
Change price per 3 month: +5.44% (8.64)
Change price per half year: +3.88% (8.77)
Change price per year: -11.64% (10.31)
Change price per 3 year: -56.64% (21.01)
Change price per 5 year: -78.03% (41.46)
Change price per 10 year: 0% (9.11)
Change price per year to date: +24.11% (7.34)
All parameters

Underestimation

Title Value Grade
P/S 15.86 1
P/BV 0.8595 9
P/E 6.56 10
EV/EBITDA -1.93 0
Total: 6

Efficiency

Title Value Grade
ROA, % -31.38 0
ROE, % -38.68 0
Total: 1.67

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.1941 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 12020.96 10
Yield Ebitda, % 273.51 10
Yield EPS, % -20.39 0
Total: 8
More

Transaction date Date of disclosure Insider Type Price Volume Quantity Share before, % Share after, % Document
02.12.2024 04.12.2024 de Verneuil Vanina
EVP and General Counsel		 Sale 8.22 625 76 0 0 link
03.04.2024 04.04.2024 De Backer Marianne
Chief Executive Officer		 Sale 9.46 690 533 72995 0 -0.06 link
29.06.2023 30.06.2023 SVF Endurance (Cayman) Ltd
10% Owner		 Sale 25.18 2 264 740 89942 0 -0.07 link
28.06.2023 30.06.2023 SVF Endurance (Cayman) Ltd
10% Owner		 Sale 25.1 175 951 7010 0 -0.01 link
04.05.2023 05.05.2023 SVF Endurance (Cayman) Ltd
10% Owner		 Sale 25.55 2 921 180 114332 0 -0.09 link
03.05.2023 05.05.2023 SVF Endurance (Cayman) Ltd
10% Owner		 Sale 25.51 2 134 520 83674 0 -0.06 link
23.02.2023 24.02.2023 Rice Steven J.
Chief Administrative Officer		 Sale 25.97 46 616 1795 0 0 link
23.02.2023 24.02.2023 Pang Phillip
Chief Medical Officer		 Sale 25.97 74 742 2878 0 0 link
15.02.2023 17.02.2023 SVF Endurance (Cayman) Ltd
10% Owner		 Sale 26.75 1 042 290 38964 0 -0.03 link
02.02.2023 03.02.2023 SVF Endurance (Cayman) Ltd
10% Owner		 Sale 29.7 2 577 990 86801 0 -0.07 link
01.02.2023 03.02.2023 SVF Endurance (Cayman) Ltd
10% Owner		 Sale 29.02 1 794 420 61834 0 -0.05 link
21.11.2022 22.11.2022 SVF Endurance (Cayman) Ltd
10% Owner		 Sale 27.13 19 534 720 0 0 link
18.11.2022 22.11.2022 SVF Endurance (Cayman) Ltd
10% Owner		 Sale 27.21 687 297 25259 0 -0.02 link

Institutions Volume Share, %
Blackrock Inc. 16864579 12.54
SB INVESTMENT ADVISERS (UK) LTD 16684041 12.4
Vanguard Group Inc 12297139 9.14
State Street Corporation 6912082 5.14
Baillie Gifford and Company 3965549 2.95
Citadel Advisors Llc 3037948 2.26
AllianceBernstein L.P. 2781049 2.07
Morgan Stanley 2126279 1.58
Geode Capital Management, LLC 1886396 1.4
Bill & Melinda Gates Foundation 1559142 1.16

ETF Share, % Profitability for 1 year, % Dividends, %
Amplify Treatments Testing and Advancements ETF 3.14 10.31 1.06
Global X Genomics & Biotechnology ETF 1.20892 2.58 0.15585
AGFiQ US Market Neutral Momentum Fund 1.09 -16.42 2.58
Virtus LifeSci Biotech Clinical Trials ETF 0.59305 63.04 0.33
Invesco S&P SmallCap Health Care ETF 0.48973 10.25 0.41696
JPMorgan Market Expansion Enhanced Equity ETF 0.22197 29.85 1.69513
VictoryShares US Small Mid Cap Value Momentum ETF 0.14919 36.19 1.97666
Syntax Stratified SmallCap ETF 0.11777 13.51 1.639
Vanguard S&P Small-Cap 600 Value ETF 0.11 12.06 2.40883
SPDR S&P 600 Small Cap Value ETF 0.10459 11.01 2.34209
Invesco Nasdaq Biotechnology ETF 0.10401 28.58 0.8565
Future Tech ETF 0.1033 426.34 0.8416
Principal Healthcare Innovators ETF 0.1033 618.5 0.8416
Direxion Daily S&P Biotech Bull 3x Shares 0.09586 4067.92 0.25924
Avantis U.S Small Cap Equity ETF 0.09534 27.77 1.68271
SPDR S&P Kensho New Economies Composite ETF 0.08101 21.57 0.88486
SPDR S&P SmallCap 600 ESG ETF 0.07877 18.95 1.85316
ProShares Ultra Nasdaq Biotechnology 0.07053 51.7 0.85651
Invesco FTSE RAFI US 1500 Small-Mid ETF 0.06286 17.58 1.75869
Vanguard S&P Small-Cap 600 ETF 0.06 13.46 1.89226
SPDR Portfolio S&P 600 Small Cap ETF 0.05232 13.05 1.84119
JPMorgan BetaBuilders U.S. Small Cap Equity Fund 0.04848 24.75 1.59225
Pacer BioThreat Strategy ETF 0.03864 21.06 1.65371
ProShares Ultra SmallCap600 0.03686 49.8 1.83727
iShares Morningstar Small Cap Value ETF 0.03119 26.7 2.50476
iShares Morningstar Small-Cap Value ETF 0.03119 201.65 2.50476
Vanguard Russell 2000 ETF 0.03 17.16 1.48801
Schwab U.S. Small-Cap ETF 0.01845 17.47 1.51433
iShares Morningstar Small-Cap ETF 0.01572 30.1 1.60498
iShares Morningstar Small-Cap ETF 0.01572 391.25 1.60498
Schwab Fundamental U.S. Small Company ETF 0.0157 13.84 1.94914
Dimensional U.S. Targeted Value ETF 0.01545 26.01 1.93487
ProShares UltraPro Russell2000 0.01501 89.82 1.47873
iShares U.S. Tech Breakthrough Multisector ETF 0.01311 21.8 0.73986
Humankind US Stock ETF 0.01289 18.81 1.99919
Fidelity MSCI Health Care Index ETF 0.01107 3 1.46057
FlexShares Morningstar US Market Factor Tilt Index Fund 0.00568 21.94 1.69572
SPDR S&P 1500 Value Tilt ETF 0.00563 27.15 2.3833
ProShares Hedge Replication ETF 0.00427 5.92 1.47892
Invesco S&P SmallCap 600 Revenue ETF 0.00415 30.92 1.94562
Avantis U.S. Equity ETF 0.00394 23.04 1.59151
Dimensional U.S. Core Equity 2 ETF 0.00279 30.76 1.47098
Dimensional US Core Equity Market ETF 0.0015 30.98 1.40618
Schwab U.S. Broad Market ETF 0.00135 24.86 1.43354
SPDR Portfolio S&P 1500 Composite Stock Market ETF 0.00113 24.29 1.46083
Dimensional U.S. Equity ETF 0.00111 31.53 1.3557
Schwab Fundamental U.S. Broad Market Index ETF 0.0011 -57.77 2.19075
iShares Russell 3000 ETF 0.00106 24.83 1.43482
SPDR Portfolio MSCI Global Stock Market ETF 0.00072 17.99 2.19607
SPDR S&P 1500 Momentum Tilt ETF 0.00006 38.25 1.12176
Vanguard ESG U.S. Stock ETF 0 23.54 1.26927
Vanguard Russell 3000 ETF 0 31.87 1.43817



Head Job title Payment Year of birth
Dr. Klaus Frueh Ph.D. Co-Founder & Scientific Advisor 177.66k 1960 (65 years)
Dr. Louis J. Picker M.D. Co-Founder & Scientific Advisor N/A
Dr. Ann M. Hanly Ph.D. Executive VP & Chief Technology Officer 842.23k 1970 (55 years)
Dr. Lawrence Corey M.D. Co-Founder & Scientific Advisor N/A 1947 (78 years)
Ms. Heather Rowe Armstrong Vice President of Investor Relations N/A
Dr. Marianne De Backer M.B.A., M.Sc., Ph.D. CEO & Director N/A 1969 (56 years)
Ms. Vanina De Verneuil J.D. Executive VP, General Counsel & Corporate Secretary N/A
Dr. Jennifer Eileen Towne Ph.D. Executive VP & Chief Scientific Officer N/A
Dr. Jeff Calcagno M.D. Executive VP & Chief Business Officer 1961 (64 years)
Ms. Arran Attridge Senior Vice President of Corporate Communications

Address: United States, San Francisco, CA , 499 Illinois Street - open in Google maps, open in Yandex maps
Website: https://www.vir.bio